What are the post-operative complications for Transcatheter Aortic Valve Replacement (TAVR)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 29, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Post-operative complications following Transcatheter Aortic Valve Replacement (TAVR) include both immediate and delayed issues that require vigilant monitoring, with vascular complications, cardiac conduction abnormalities, stroke, paravalvular leak, acute kidney injury, and coronary obstruction being among the most significant concerns. According to the most recent and highest quality study, 1, the Valve Academic Research Consortium 3 introduces a new category of complications deemed to capture and classify injury of any cardiac structure occurring during the procedure. These complications can be major or minor and include injury involving the aortic annulus, left ventricle outflow tract, ventricular septum, left or right ventricle, left or right atrium, mitral valve apparatus, tricuspid valve apparatus, and coronary sinus.

Some of the key complications and their management strategies include:

  • Vascular complications at the access site, such as bleeding, hematoma formation, or vessel damage requiring repair
  • Cardiac conduction abnormalities, which occur in 10-30% of patients and may necessitate permanent pacemaker implantation, especially with self-expanding valves
  • Stroke, a serious complication affecting 2-5% of patients due to embolization during the procedure
  • Paravalvular leak, which may develop when the prosthetic valve doesn't seal completely against the native annulus, causing regurgitation
  • Acute kidney injury, resulting from contrast exposure or hypoperfusion during the procedure
  • Coronary obstruction, which can occur if the valve displaces native leaflet tissue over coronary ostia

The management of these complications typically involves a multidisciplinary approach, including the use of dual antiplatelet therapy, regular echocardiographic follow-up, and careful monitoring for signs of complications. As noted in 1, the choice of intervention, including TAVR or surgical AVR, should be made by a heart valve team consisting of an integrated, multidisciplinary group of healthcare professionals with expertise in valvular heart disease, cardiac imaging, interventional cardiology, cardiac anesthesia, and cardiac surgery.

In terms of specific management strategies, patients may require:

  • Dual antiplatelet therapy with aspirin (81mg daily indefinitely) and clopidogrel (75mg daily for 3-6 months)
  • Regular echocardiographic follow-up at 30 days, 6 months, 1 year, and annually thereafter to monitor valve function and detect complications early
  • Careful monitoring for signs of complications, such as bleeding, stroke, or cardiac conduction abnormalities
  • Prompt intervention, including surgical or percutaneous repair, in the event of a complication.

Overall, the management of post-operative complications following TAVR requires a comprehensive and multidisciplinary approach, with careful attention to the potential risks and benefits of different management strategies.

From the Research

Post-Operative Complications of TAVR

The post-operative complications of Transcatheter Aortic Valve Replacement (TAVR) include:

  • Hypotension 2
  • Vascular injury 2
  • Anemia 2
  • Stroke 2, 3
  • New-onset atrial fibrillation 2
  • Conduction disturbances 2, 4
  • Kidney injury 2
  • Major bleeding 5
  • Vascular complications 5
  • Paravalvular leak 4

Management of Complications

The management of these complications requires careful consideration and planning, including:

  • Intensive care after TAVR 2
  • Periprocedural anesthetic considerations 6
  • Optimal pharmacological management after the procedure 4
  • Management of coexistent coronary artery disease 3
  • Prevention of periprocedural stroke 3

Recent Updates and Considerations

Recent updates and considerations in TAVR include:

  • Expansion of indications to lower risk patients 3, 4
  • Advances in technology and technique 3, 4
  • Improvements in safety and reduction of procedural complications 4
  • Long-term durability and bioprosthetic valve performance 4
  • Coronary reaccess and reintervention after TAVR 4

Related Questions

What antibiotic is recommended for a new Transcatheter Aortic Valve Replacement (TAVR) patient undergoing a contaminated or dirty procedure?
Is Flagyl (metronidazole) indicated for a new Transcatheter Aortic Valve Replacement (TAVR) patient undergoing a contaminated or dirty procedure?
Is a patient with a history of Hypertension (HTN), Hyperlipidemia (HLD), Diabetes Mellitus type 2 (DM 2), Benign Prostatic Hyperplasia (BPH), and Aortic Stenosis (AS) status post Transcatheter Aortic Valve Replacement (TAVR) cleared for Transurethral Resection of the Prostate (TURP) and total left knee replacement surgeries from a cardiovascular standpoint?
When should a patient start physical rehabilitation or exercises after a Transcatheter Aortic Valve Replacement (TAVR) procedure?
What is the next step in managing an 89-year-old male with exertional dyspnea, history of hypertension and severe aortic stenosis status post TAVR, and newly diagnosed COPD?
What are the treatment options for a 16-year-old female presenting with menorrhagia (heavy menstrual bleeding) and dysmenorrhea (painful menstrual cycles)?
Is administration of beta blockers (beta-adrenergic blocking agents) recommended prior to left heart catheterization?
What is the post-operative treatment for Transcatheter Aortic Valve Replacement (TAVR)?
What is the evaluation approach for a 34-year-old female presenting with secondary amenorrhea (absence of menstruation) and difficulty losing weight despite regular exercise?
Is anticoagulation (Anti-Coagulation) therapy required with a bioprosthetic (Bio-Prosthetic) valve?
Which medication is least useful in the treatment of Hypertrophic Cardiomyopathy (HCM): Verapamil, Digoxin, Disopyramide, or Beta blockers?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.